menu
    • menu
    [{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Hangzhou Jiuyuan Gene Engineering

    Menu

    Hangzhou Jiuyuan Gene Engineering

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

                            Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            China's First Biosimilar Ozempic Drug Applies for Approval

                            Details : Jiyoutai (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

                            Product Name : Jiyoutai

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 03, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

                            Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

                            Details : Pegfilgrastim is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neutropenia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 07, 2013

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hangzhou Jiuyuan Gene Engineering

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients

                            Details : Pegfilgrastim is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neutropenia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 11, 2012

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth